NEW YORK: despite a good start to the holiday-shortened reporting period to December 1 (markets were closed on November 27 for Thanksgiving), shares went into free-fall on the last day as the problems of the financial and automobile sectors, as well as the economy came back into focus, leaving the Dow Jones 3.5% lower overall. Drug and biotechnology stocks suffered along with the rest of the market, with just four of those tracked seeing a rise and 31 falling week-on-week.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
A biotechnology company, based in China, developing car-t-based therapeutics for haematological and metabolic and endocrine diseases with a focus on addressing unmet medical need.
Stock Commentary - New York week to Dec 1, 2008
NEW YORK: despite a good start to the holiday-shortened reporting period to December 1 (markets were closed on November 27 for Thanksgiving), shares went into free-fall on the last day as the problems of the financial and automobile sectors, as well as the economy came back into focus, leaving the Dow Jones 3.5% lower overall. Drug and biotechnology stocks suffered along with the rest of the market, with just four of those tracked seeing a rise and 31 falling week-on-week.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
| Headless Content Management with Blaze